IMMONC
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
IMMONC
May 30, 2024, 10:57 |
Insight
Julia Hoveyan: A year ago, the IMMONC launched the first-ever investigator-sponsored trial in pediatric oncology in Armenia
Ruzanna Papyan recently shared a post by Julia Hoveyan, Pediatric Oncologist at the Pediatric Cancer…
Apr 15, 2024, 04:04 |
Blog
Amalya Sargsyan: Proud to see IMMONC spotlighted in ASCO's latest policy statement on global equity in clinical trials
Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, posted on LinkedIn: "Extremely proud to…
Feb 14, 2024, 13:40 |
Insight
Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer
Karen Bedirian, Projects Director at Immune Oncology Research Institute, shared on LinkedIn: "Happy to share…
Feb 8, 2024, 16:56 |
Blog
IV Armenian Oncology Congress: 6 tweets from Shushan Hovsepyan
Shushan Hovsepyan, Pediatric Oncologist and Clinical Research Coordinator at the Yeolyan Hematology and Oncology Center,…
Jan 15, 2024, 08:37 |
Career
Jemma Arakelyan: I have been ranked in the top 5% of PG researchers and have received Excellent Paper Awards
Jemma Arakelyan, CEO of the Institute of Cancer and Crisis, shared on LinkedIn: "Delighted to…
Jun 13, 2023, 17:24 |
Insight
In 16 months, we have registered more cancer clinical trials in Armenia, than throughout all the years before that - Gevorg Tamamyan
Last year, on February 4th I was doing a presentation about the cancer clinical trials…
All:
6
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube